Leap Therapeutics (LPTX) Misses Q2 EPS by 40c

Leap Therapeutics (NASDAQ: LPTX) reported Q2 EPS of ($0.40), $0.40 worse than the analyst estimate of $0.00.

For earnings history and earnings-related data on Leap Therapeutics (LPTX) click here.

You May Also Be Interested In

• Evercore ISI Starts Credo Tech (CRDO) at Outperform
• Sanofi (SNY) call put ratio 8.4 calls to 1 put with a focus on July 45 calls
• Fervo Energy, Nvidia, and PNNL to build geothermal digital twin